Redeye leaves a comment following Alzinova’s announced study results form the phase Ib extension study (part B) with its vaccine candidate ALZ-101. We are encouraged to learn that the long-term data reinstates the positive analysis from the initial part of the study (Part A), suggesting that ALZ-101 is well-tolerated and safe, elicits a high immune response in patients and shows indications of efficacy on cognitive and functional parameters.

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se